Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
Moderna to provide investigational mRNA CN-1 therapy free of chargeCAMBRIDGE, Mass. & STAMFORD, Conn., September 07, 2021--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering...